27. (Amended) A conjugate according to claim 26 wherein the α-emitting radionuclide is astatine-211, bismuth-212, or bismuth-213.

28. (Amended) A conjugate according to claim 20 wherein the molecule which induces blood coagulation and/or blood vessel occlusion comprises a photosensitizer and a radionuclide.

29. (Amended) A method for the treatment of an angiogenesis-related pathology, comprising administering to a patient in need thereof a conjugate according to claim 20.

30. (Amended) A method for the treatment of an angiogenesis-related pathology, comprising administering to a patient in need thereof a conjugate according to claim 22, followed by irradiation.

31. (Amended) A method according to claim 30 wherein the angiogenesis-related pathology is an ocular disorder.

32. (Amended) A method for the treatment of an angiogenesis-related pathology, comprising administering to a patient in need thereof a conjugate according to claim 25.

33. (Amended) A method according to claim 32 wherein the radionuclide is astatine-211.

34. (Amended) A method for the treatment of an angiogenesis-related pathology, comprising administering to a patient in need thereof a conjugate according to claim 28.

Please add the following new claims 36-48 as indicated below.

36. A conjugate according to claim 20, wherein said affinity is in the subnamomolar range.

37. A conjugate according to claim 36 wherein the molecule which induces blood coagulation and blood vessel occlusion is a photoactive molecule.

38. A conjugate according to claim 37 wherein the photoactive molecule is a photosensitizer.

39. A conjugate according to claim 38 wherein the photosensitizer absorbs at a wavelength above 600 nm.

40. A conjugate according to claim 38 wherein the photosensitizer is a tin (IV) chlorine e_6 molecule.

41. A conjugate according to claim 36, wherein the antibody is an scFv antibody.

42. A conjugate according to claim 36, wherein the antibody is a recombinant antibody.

43. A conjugate according to claim 41, wherein the antibody comprises a limited number of mutations in its CDR residues.

44. A conjugate according to claim 43, wherein the mutated residues are residues 31-33, 50, 52 and/or 54 of its VH domain and/or residues 32 and/or 50 of its VL domain.

45. A conjugate according to claim 36, wherein the antibody binds to the ED-B domain of fibronectin with a K_d of about 54 pM.

46. A conjugate according to claim 36, wherein the antibody has the following amino acid sequence:

VH domain (SEQ ID NO: 19)
EVQLLESGGG LVQPGGSLRL SCAASGFTFS
SFSMSWVRQA PGKGLEWVSS ISGSSGTTYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED
TAVYYCAKPF PYFDYWGQGT LVTVSS

C5

linker (SEQ ID NO: 20)
GDGSSGGSGGASTG

VL domain (SEQ ID NO:21)
EIVLTQSPGT LSLSPGERAT LSCRASQSVS
SSYLAWYQQK PGQAPRLLIY YASSRATGIP
DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ
QTGRIPPTFG QGTKVEIK

47. A conjugate according to claim 36, wherein said affinity is about 0.05 nM.

48. A method of treating a tumor or a disease characterized by vascular proliferation, comprising administering to a patient in need thereof an antibody with a specific, high affinity for the ED-B domain of fibronectin.

REMARKS

Declaration/Power of Attorney

Attached is a substitute Declaration/Power of Attorney which correctly claims priority under 35 USC 120.